Nektar Therapeutics

XTRA:ITH0 Stock Report

Market Cap: €2.2b

Nektar Therapeutics Management

Management criteria checks 1/4

Nektar Therapeutics' CEO is Howard Robin, appointed in Jan 2007, has a tenure of 19.58 years. total yearly compensation is $6.26M, comprised of 17.7% salary and 82.3% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth €3.50M. The average tenure of the management team and the board of directors is 1.6 years and 18 years respectively.

Key information

Howard Robin

Chief executive officer

US$6.3m

Total compensation

CEO salary percentage17.68%
CEO tenure19.6yrs
CEO ownership0.2%
Management average tenure1.6yrs
Board average tenure18yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Howard Robin's remuneration changed compared to Nektar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$158m

Dec 31 2025US$6mUS$1m

-US$164m

Sep 30 2025n/an/a

-US$121m

Jun 30 2025n/an/a

-US$122m

Mar 31 2025n/an/a

-US$133m

Dec 31 2024US$4mUS$1m

-US$119m

Sep 30 2024n/an/a

-US$168m

Jun 30 2024n/an/a

-US$177m

Mar 31 2024n/an/a

-US$176m

Dec 31 2023US$3mUS$1m

-US$276m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$307m

Mar 31 2023n/an/a

-US$415m

Dec 31 2022US$11mUS$1m

-US$368m

Sep 30 2022n/an/a

-US$454m

Jun 30 2022n/an/a

-US$525m

Mar 31 2022n/an/a

-US$491m

Dec 31 2021US$11mUS$1m

-US$524m

Sep 30 2021n/an/a

-US$495m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$429m

Dec 31 2020US$11mUS$1m

-US$444m

Sep 30 2020n/an/a

-US$439m

Jun 30 2020n/an/a

-US$429m

Mar 31 2020n/an/a

-US$460m

Dec 31 2019US$10mUS$1m

-US$441m

Compensation vs Market: Howard's total compensation ($USD6.26M) is above average for companies of similar size in the German market ($USD2.11M).

Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.

CEO

Howard Robin (73 yo)

19.6yrs
Tenure
US$6,256,954
Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director19.6yrsUS$6.26m0.16%
€ 3.6m
Jonathan Zalevsky
Senior VP and Chief Research & Development Officer6.8yrsUS$2.32m0.029%
€ 645.4k
Linda Rubinstein
CFO and Principal Financial & Accounting Officerless than a yearno datano data
Jason Barnard
Chief Accounting Officer1.6yrsno datano data
Elizabeth Zhang
VP of Legalless than a yearno datano data
Robert Bacci
Chief People Officer and Head of Quality & Facilities4.7yrsno datano data
Jennifer Ruddock
Chief Business Officer7.6yrsno datano data
Mary Tagliaferri
Chief Medical Officerless than a yearno datano data
Ken Franke
Senior Vice President of Biologics Process Development & Manufacturing1.6yrsno datano data
Charleen Jue
Senior Vice President of Clinical Development Operations1.6yrsno datano data
Takahiro Miyazaki
Senior VP & Head of Research1.6yrsno datano data
Vivian Wu
Investor Relationsno datano datano data
1.6yrs
Average Tenure
59.5yo
Average Age

Experienced Management: ITH0's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director19.5yrsUS$6.26m0.16%
€ 3.6m
Robert Chess
Independent Chairman of the Board34.3yrsUS$489.38k0.050%
€ 1.1m
R. Greer
Independent Director16.5yrsUS$465.63k0.060%
€ 1.3m
Roy Whitfield
Lead Independent Director26yrsUS$470.88k0.057%
€ 1.3m
Jeffrey Ajer
Independent Director8.9yrsUS$440.88k0.0067%
€ 150.6k
Diana Brainard
Independent Director4.8yrsUS$445.63k0.0056%
€ 126.0k
18.0yrs
Average Tenure
68.5yo
Average Age

Experienced Board: ITH0's board of directors are seasoned and experienced ( 18 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/09 01:35
End of Day Share Price 2026/08/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research